Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis' Zia On Momentum Amid Policy Strain In India

Executive Summary

As Novartis continues to battle Glivec-related pain in India, its country president Jawed Zia tells Scrip that the Swiss multinational has been hit "particularly hard" after the government withdrew customs duty exemptions on more than 70 drugs including imatinib mesylate earlier this year.


Related Content

Novartis Rejiggers Pharma To Favor Oncology
India's New IPR Policy: Balanced And Evolving?